These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112 [TBL] [Abstract][Full Text] [Related]
13. Triazolopyridazine LRRK2 kinase inhibitors. Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015 [TBL] [Abstract][Full Text] [Related]
14. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models. Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787 [TBL] [Abstract][Full Text] [Related]
15. Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. Salado IG; Zaldivar-Diez J; Sebastián-Pérez V; Li L; Geiger L; González S; Campillo NE; Gil C; Morales AV; Perez DI; Martinez A Eur J Med Chem; 2017 Sep; 138():328-342. PubMed ID: 28688273 [TBL] [Abstract][Full Text] [Related]
16. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy. Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038 [TBL] [Abstract][Full Text] [Related]
17. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745 [TBL] [Abstract][Full Text] [Related]
18. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184 [TBL] [Abstract][Full Text] [Related]